SCHEMBL25812002

SCHEMBL25812002

CN(CCN1CCC1)C(=O)c1ccc2[nH]c3c(c2c1)CCCC3

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.54
LMNA P02545 6/20 0.54
MAPT P10636 6/20 0.54
ALDH1A1 P00352 5/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
POLB P06746 4/20 0.52
TP53 P04637 1/20 0.50
CASP1 P29466 1/20 0.50
F2 P00734 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
MAPK1 P28482 2/20 0.46
GAA P10253 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25811968 0.98 LMNA (0.54) KDM4ELMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL25811982 0.97 MAPT (0.53) KDM4ELMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL25811972 0.96 LMNA (0.51) KDM4ELMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL25811835 0.94 LMNA (0.52) KDM4ELMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL25811965 0.92 MAPT (0.52) KDM4ELMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL25815140 0.92 MEN1 (0.49) KDM4ELMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL25811720 0.90 KDR (0.49) KDM4ELMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL25815092 0.85 KDM4E (0.59) KDM4ELMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL25813810 0.83 KDM4E (0.56) KDM4ELMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL25811987 0.81 KMT2A (0.58) KDM4EMAPTALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES GALYAN BIO INC (US) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES HTT, HYPK, PARK7 KDM4E 1465/4885LMNA 2606/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.